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Report on planning comparison 
of VMAT, IMRT and helical tomotherapy 
for the ESCALOX-trial pre-study
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Michal Devecka1, Kerstin K. Kessel1, Stephanie E. Combs1,2 and Jan J. Wilkens1
Abstract 
Background: The ESCALOX trial was designed as a multicenter, randomized prospective dose escalation study for 
head and neck cancer. Therefore, feasibility of treatment planning via different treatment planning systems (TPS) and 
radiotherapy (RT) techniques is essential. We hypothesized the comparability of dose distributions for simultaneous 
integrated boost (SIB) volumes respecting the constraints by different TPS and RT techniques.
Methods: CT data sets of the first six patients (all male, mean age: 61.3 years) of the pre-study (up to 77 Gy) were 
used for comparison of IMRT, VMAT, and helical tomotherapy (HT). Oropharynx was the primary tumor location. 
Normalization of the three step SIB (77 Gy, 70 Gy, 56 Gy) was D95% = 77 Gy. Coverage (CVF), healthy tissue conform-
ity index (HTCI), conformation number (CN), and dose homogeneity (HI) were compared for PTVs and conformation 
index (COIN) for parotids.
Results: All RT techniques achieved good coverage. For SIB77Gy, CVF was best for IMRT and VMAT, HT achieved 
highest CN followed by VMAT and IMRT. HT reached good HTCI value, and HI compared to both other techniques. For 
SIB70Gy, CVF was best by IMRT. HTCI favored HT, consequently CN as well. HI was slightly better for HT. For SIB56Gy, 
CVF resulted comparably. Conformity favors VMAT as seen by HTCI and CN. Dmean of ipsilateral and contralateral 
parotids favor HT.
Conclusion: Different TPS for dose escalation reliably achieved high plan quality. Despite the very good results of HT 
planning for coverage, conformity, and homogeneity, the TPS also achieved acceptable results for IMRT and VMAT.
Trial registration ClinicalTrials.gov Identifier: NCT 01212354, EudraCT-No.: 2010-021139-15. ARO: ARO 14-01
Keywords: Dose escalation, Head and neck cancer, Combined chemoradiation therapy, RT planning comparison, 
IMRT, VMAT, Helical tomotherapy, SIB
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Background
Head and neck cancer patients are treated by intensity 
modulated radiotherapy (IMRT) as standard of care in 
radiation oncology. Early in the era of IMRT application, 
the concept of the simultaneous integrated boost (SIB) 
was evaluated [1]. This boost technique creates a selective 
heterogeneous dose distribution in one target divided 
into subvolumes with the aim of better conformity [2]. 
Many results of planning comparisons using different 
treatment planning systems (TPS) and radiotherapy (RT) 
treatment concepts have been published for both head 
and neck as well as other cancer. Many of these used real 
patient data sets for comparison of treatment modali-
ties at the same institution [3–9]. IMRT, volumetric 
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modulated arc therapy (VMAT), and helical tomotherapy 
(HT) are routinely used to treat patients with head and 
neck cancer.
In multicenter prospective trials with IMRT, quality 
assurance (QA) of RT planning is mandatory [10, 11]. 
QA for RT of head and neck cancer does not only include 
the quality of RT plans, but begins earlier in the treat-
ment process. The delineation of the target and organ 
at risk (OAR) requires standardization and quality con-
trol. Especially with the implementation of RT plans with 
steep dose gradients, the correct target volume delinea-
tion is of outstanding importance. Otherwise the clinical 
outcome of head and neck cancer patients is compro-
mised [11]. Feasibility of the RT-strategy is the first step 
of RT-trial design. The second step is the proof of dose 
specification with different TPS, followed by a dummy 
run of all participating trial centers including a dummy 
run for target volume and OAR contouring.
The ESCALOX trial was planned as a multicenter trial 
for dose escalation in head and neck cancer to the gross 
tumor volume (GTV) defined by CT and MRI imaging 
in 2010. FMISO-PET was part of a translational research 
project and not implemented in target volume defini-
tion. Data sets of the first six patients of the pre-study as 
determined by the German Federal Office of Radiation 
Protection (Bundesamt für Strahlenschutz—BfS) (BfS-
registration number Z5-22463/2-2011-011) were used 
for planning comparison with different TPS. The aim 
of this planning study was to compare the non-uniform 
dose prescription and calculated planning target volume 
(PTV) doses of the different SIB volumes as well as the 
calculated doses to the OARs between two TPS: Eclipse 
version 13.0 (Varian Medical Systems, Palo Alto, CA, 
USA) for VMAT (RapidArc) and dynamic multi-field 
IMRT, and TomoTherapy Planning Station version 4.2.3 
(Accuray, Sunnyvale, CA, USA).
The hypothesis of this investigation was the genera-
tion of comparable RT plans via different TPS and RT 
techniques respecting the dose prescription to the SIB 
volumes as a primary objective. The secondary planning 
goal was the concurrent minimization of dose to the 
organs at risk (OAR) while having an escalated dose of up 
to 77 Gy in the SIB.
Methods
Patient characteristics and RT concept
Patients were treated between 1/2016 and 2/2017 after 
inclusion in the pre-study of the ESCALOX trial at the 
Department of Radiation Oncology of the Technical 
University of Munich. All included patients were male 
with a smoking history of more than 10 packyears. The 
mean age was 61.3 years [53–70 years]. In all cases, pri-
mary tumor location was the oropharynx, for details, see 
Table  1. TNM classification was done according to the 
7th edition of UICC, 2010. The mean GTV of primary 
tumor was 62.6 cm3 [IQR 22.4–116.4 cm3]. Concomitant 
platin-based chemotherapy was standard of care in all 
patients. All patients were treated with 35 fractions with 
5 fractions per week. Because of the three step SIB con-
cept, each target volume was deemed as SIB: SIB77Gy: 
2.2  Gy up to 77  Gy; SIB70Gy: 2.0  Gy up to 70  Gy and 
SIB56Gy: 1.6 Gy up to 56 Gy (for details see [12]).
Target delineation
Head and shoulder mask systems were customized before 
treatment planning CT for all patients (slice thickness 
3  mm, intravenous contrast enhancement in all cases). 
CT extension comprised base of skull to mid-mediasti-
num. The CT images were reconstructed with 512 × 512 
pixel matrices.
Before treatment planning, every patient was also 
staged by means of a head and neck MRI. These MRI 
scans were co-registered to the planning CT. Based on 
the panendoscopy report and the imaging entirety, the 
GTV, clinical target volume (CTV), and SIB (PTV) were 
delineated and crosschecked by two radiooncologists 
(MD, SP). Bilateral neck lymph drainage was PTV in all 
cases. Every isotropic margin generation by the TPS was 
re-contoured manually with respect to anatomic struc-
tures (bones, ligaments, cartilage, muscle) usually not 
tumor-invaded as recommended by trial protocol. The 
RT plans were evaluated quantitatively and qualitatively 
(isodose curves and color wash) by two physicians.
Treatment planning—VMAT, IMRT, HT
All plans were calculated, optimized, and approved by 
experienced medical physicists on the particular sys-
tem (Eclipse for VMAT and IMRT, and TomoTherapy 
Planning Station for HT). Normalization was done to 
95% of the volume with the highest prescribed dose 
(SIB77). In the tomotherapy planning workflow, nor-
malization is done during the optimization process. 
Hence, there can be small discrepancies between the 
“normalization dose” and the dose after final dose cal-
culation (after which the dose will not be normalized 
again). The first optimization goal was to bring 95% of 
the PTV to the specific prescribed doses (Table  2). In 
addition, 50% of the PTV volumes (SIB77Gy, SIB70Gy, 
SIB56Gy) were to receive no more than 79.3  Gy, 
72.1 Gy, and 57.7 Gy, respectively. The second planning 
objective was to spare the following OARs according 
to their constraints or to the ALARA principle: spinal 
cord (spinal cord + 5 mm) (mandatory), brachial plexus 
(mandatory), brainstem (mandatory), optical nerve 
(mandatory), mandible, glottis, and parotid glands. 
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For OARs labeled as “mandatory”, the given dose was 
a hard constraint. In some cases, when it was not 
possible to fulfill both criteria (PTV dose and man-
datory OAR dose—see Table  3), a lower dose in the 
PTV was accepted (detailed delineation and plan-
ning are described in [12]). All planning modalities 
Table 1 Patient characteristics
Characteristics GTV = SIB77Gy 
 (cm3)
Patient 1, male
Age at diagnosis: 67 years
Diagnosis: OPC (midline of base of tongue)
TNM: cT3 cN2b cM0 G3
Histology: SCC, p16+
Treatment: CCRT once Cisplatin 40 mg/m2/day, change to 5× Carboplatin AUC 2 (only one kidney after accident)
86.8
Patient 2, male
Age at diagnosis: 70 years
Diagnosis: OPC (base of tongue right)
TNM: cT2 cN2c cM0 G3
Histology: SCC, p16−
Treatment: CCRT with 4× Cisplatin 40 mg/m2/day
77.33
Patient 3, male
Age at diagnosis: 53 years
Diagnosis: OPC (left soft palate, base of tongue, tongue left side, floor of mouth, exceeding midline)
TNM: cT4a cN2c cM0 G3
Histology: SCC, p16−
Treatment: CCRT with 6× Cisplatin 40 mg/m2/day
116.4
Patient 4, male
Age at diagnosis: 54 years
Diagnosis: OPC (left tonsil, submandibular gland, dorsal third of tongue, fossa pterygopalatina)
TNM: cT4a cN2c cM0 G3
Histology: SCC, p16−
Treatment: CCRT with 6× Cisplatin 40 mg/m2/day
24.6
Patient 5, male
Age at diagnosis: 56 years
Diagnosis: OPC (left tonsil and fossa)
TNM: cT2 cN2b cM0 G2
Histology: SCC, p16−
Treatment: CCRT with 6× Cisplatin 40 mg/m2/day
48.3
Patient 6, male
Age at diagnosis: 68 years
Diagnosis: OPC (right tonsil and soft palate)
TNM: cT4a cN2b cM0 G3
Histology: SCC, p16−
Treatment: CCRT with 3× Cisplatin 40 mg/m2/day
22.4
Table 2 ESCALOX—trial dose prescription for SIB-Volumes 
volumes
PTV (SIB) Planning goal  D95% (Gy) Planning 
goal  D50% 
(Gy)
SIB77Gy 77 ≤ 79.3
SIB70Gy 70 ≤ 72.1
SIB56Gy 56 ≤ 57.7
Table 3 Dose constraints for OAR defined by the ESCALOX 
trial protocol
OAR D95% Planning goals as accepted 
dose [EQD2]
Spinal cord (PRV: spi-
nal cord + 5 mm)
Mandatory Dmax < 50 Gy2 or
No more than 1 cm3 > 45 Gy2
Brachial plexus Mandatory 60 Gy2
Brainstem Mandatory Dmax < 54 Gy2 or
No more than 1 cm3 > 54 Gy2
Optical nerve Mandatory Dmax < 54 Gy2
Mandible Recommended Dmax < 70 Gy2 or
No more than 1 cm3 > 70 Gy2
Glottis (outside PTV) Recommended 2/3 < 50 Gy2
Dmean < 45 Gy2
Gl. parotis Recommended Dmean < 26 Gy2
D50 < 30 Gy2
20 cm3 of both < 20 Gy2
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used identical dose criteria for the SIBs and OARs as 
described in the trial protocol.
VMAT and IMRT
Treatment planning for the VMAT and dynamic IMRT 
plans was performed with the Eclipse 13.0 TPS. For 
dose calculation, the Anisotropic Analytical Algorithm 
(AAA, version 10.028) was used with a dose grid size of 
2.5 × 2.5 × 3.0 mm3. VMAT and IMRT planning was per-
formed for treatment using a Varian Clinac Trilogy lin-
ear accelerator equipped with a 120 HD MLC. VMAT 
plans consisted of three arcs with 358° rotation each. 
The sliding window IMRT plans were optimized using a 
beam set-up of nine coplanar static beam directions with 
evenly distributed angular distances.
All plans were normalized to a dose of 77  Gy, cover-
ing 95% of the SIB77Gy volume as described in the trial 
protocol [12]. There were no limits for treatment plan-
ning time. Re-optimization for treatment planning was 
allowed and recommended to push the TPS to the limits.
Helical tomotherapy
Treatment planning was done with the TomoTherapy 
Planning Station (Accuray), version 4.2.3. The tomother-
apy plans were all helical IMRT plans with field widths of 
1 cm and calculation grid size set to fine.
Dose‑volume histogram (DVH) analysis and statistics
All DVH analyses were done using the Eclipse TPS (HT 
plans were imported). DVH data was extracted to a TXT-
file and then read out by R-Software (R version 3.4.1 
(2017-06-30)—The R Foundation for Statistical Comput-
ing) and spreadsheets. Statistical analysis was calculated 
by IBM SPSS version 25. The DVH data of each patient 
was compared for every planning approach (IMRT, 
VMAT or HT) and between all patients by calculating 
the mean data for every parameter.
A comparison of the mean DVH data of all techniques 
was made by using Student’s two-sided paired t-test or 
Wilcoxon test, depending on the distribution of the val-
ues (IMRT vs. HT; IMRT vs. VMAT and HT vs. VMAT). 
Statistical significance was supposed for p ≤ 0.05.
Parameters for DVH analysis 
To compare different RT-plans (VMAT, IMRT and HT), 
the following DVH-SIB (PTV) parameters were rated: 
SIB77Gy—Dmean,  D100%,  D98%  (Dmin),  D25%,  D5% and 
 D2%  (Dmax). We defined the SIB70Gy-volume as a shell 
without the inside-located SIB77Gy-volume. For the 
SIB56Gy-volume, the same procedure was done to cre-
ate the shell without SIB70Gy- and SIB77Gy-volumes. 
For each shell (SIB56Gy and SIB70Gy),  D95% and  D5% are 
reported (Table 4) (for raw data see Additional file 1). For 
assessment of plan quality, the coverage factor (CVF), 
healthy tissue conformity index (HTCI), conformation 
number (CN) and the homogeneity index (HI) were 
calculated and compared to each other [3, 13]. These 
parameters were used to judge the quality of the different 
planning target volumes (i.e. SIB).
The formulae to calculate all these parameters are given 
with:
1 CVF—coverage factor [13] CVF = TVRI
TV
 TVRI—irradiated target volume encompassed by ref-
erence dose 95%-isodose; TV—target volume.




 VRI—irradiated volume encompassed by reference 
95%-isodose.
3 CN—conformation number [15] CN = CVF × HTCI
4 HI—homogeneity index [13] HI = D5%
D95%
 Parameters for OAR for head and neck cancer were 
reported from DVH and also compared depending 
on the RT technique (parallel OAR: parotid gland 
 Dmean [16–18]; larynx  Dmean [19], serial OAR: spinal 
cord + 5  mm  Dmax; brainstem  Dmax, plexus brachia-
lis  D2%, mandibula  Dmean and  D2%). In order to prop-
erly assess the OAR doses of the parotid gland, it is 
important to note that three patients had left-sided 
and two patients right-sided cancer of the orophar-
ynx. In one case, the tumor was located near the 
midline with growth to the right. In this way, we used 
“ipsilateral” parotid gland as the site of primary tumor 
location and contralateral for the primary tumor free 
zone. In order to compare the parotid glands (ipsi- or 
contralateral to the primary tumor), the conformity 
index was used.
5 COIN—conformity index according to Baltas et  al. 
[20]




 VOARref OAR volume receiving reference dose;  VOAR 
total volume of OAR.
Results
All RT plans achieved good to excellent coverage (CVF) 
for the SIB-volumes. SIB77Gy for IMRT and VMAT 
had a CVF value of 1.0 and HT achieved a CVF value of 
0.997 ± 0.007. HT yielded best HTCI (HT 0.372 ± 0.034 
vs. VMAT 0.254 ± 0.103 vs. IMRT 0.273 ± 0.123) and 
CN (HT 0.371 ± 0.033 vs. VMAT 0.254 ± 0.103 vs. IMRT 
0.273 ± 0.123), see Table 4.
As for coverage and conformity, HT achieved the best 
result for dose homogeneity (HI: HT 1.032 ± 0.013 vs. 
VMAT 1.054 ± 0.003 vs. IMRT 1.054 ± 0.006).
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Table 4 Treatment planning results: Dose-volume histogram parameters and  coverage, conformity and  homogeneity 
indices for VMAT, IMRT, and HT (mean ± SD); ipsilateral corresponds to the tumor site, contralateral to the opposite side 
of tumor location
Volume Para‑meter Unit VMAT IMRT HT p‑value
IMRT vs. HT IMRT vs. VMAT HT vs. VMAT
SIB77Gy Volume cm3 (range) 54.2 ± 35.5
Median 37.7
Dmean Gy 79.1 ± 0.2 79.2 ± 0.2 78.5 ± 0.7 0.048 0.3 0.018
D100% Gy 72.9 ± 1.0 72.7 ± 0.7 73.6 ± 1.7 0.3 0.3 0.5
D98% Gy 76.3 ± 0.2 76.3 ± 0.2 76.2 ± 1.3 0.9 0.5 0.9
D95% Gy 77.0 ± 0 77.0 ± 0 77.2 ± 0.1 0.6 0.1 0.6
D2% Gy 81.6 ± 0.2 81.5 ± 0.5 79.8 ± 1.0 0.015 0.9 0.013
D5% Gy 81.2 ± 0.2 81.2 ± 0.5 79.6 ± 1.0 0.026 1.0 0.017
Coverage CVF 1 ± 0.00 1 ± 0.00 0.997 ± 0.007
Conformity HTCI 0.25 ± 0.10 0.27 ± 0.11 0.37 ± 0.03
CN 0.25 ± 0.10 0.27 ± 0.11 0.37 ± 0.03
Homogeneity HI 1.054 ± 0.003 1.054 ± 0.006 1.032 ± 0.012
SIB70Gy (excluding SIB77Gy) Volume cm3 257.4 ± 112.7
Median 220.7
D95% Gy 69.5 ± 0.2 69.8 ± 0.3 69.1 ± 0.8 0.2 0.2 0.4
D5% Gy 77.8 ± 0.2 76.9 ± 0.6 76.7 ± 0.4 0.1 0.6 0.044
Coverage CVF 0.995 ± 0.002 0.997 ± 0.002 0.995 ± 0.005
Conformity HTCI 0.759 ± 0.026 0.773 ± 0.032 0.827 ± 0.031
CN 0.754 ± 0.024 0.769 ± 0.032 0.823 ± 0.032
Homogeneity HI 1.145 ± 0.01 1.142 ± 0.008 1.141 ± 0.015
SIB56Gy (excluding SIB70Gy) Volume cm3 (range) 691.9 ± 181.2
Median 653.5
D95% Gy 55.4 ± 0.2 55.3 ± 0.4 55.4 ± 0.5 1.0 0.5 0.4
D5% Gy 69.3 ± 0.3 68.9 ± 0.8 67.5 ± 0.8 0.5 0.1 0.015
Coverage CVF 0.986 ± 0.004 0.985 ± 0.004 0.983 ± 0.005
Conformity HTCI 0.747 ± 0.024 0.731 ± 0.027 0.728 ± 0.031
CN 0.739 ± 0.023 0.723 ± 0.029 0.719 ± 0.031
Homogeneity HI 1.391 ± 0.018 1.384 ± 0.018 1.381 ± 0.020
Organs at risk
Parotid Glands both COIN 0.606 ± 0.040 0.593 ± 0.032 0.603 ± 0.065
ipsilateral Dmean Gy 32.8 ± 4.8 33.1 ± 4.4 31.1 ± 4.0 0.046 0.345 0.043
Volume cm3 30.4 ± 6.0
COIN 0.555 ± 0.047 0.548 ± 0.040 0.546 ± 0.073 0.917 0.345 0.753
Contralateral Dmean Gy 26.3 ± 3.9 26.2 ± 3.6 22.6 ± 5.5 0.116 0.173 0.043
Volume cm3 26.9 ± 5.5
COIN 0.665 ± 0.043 0.647 ± 0.040 0.664 ± 0.063 0.345 0.028 0.917
Spinal cord + 5 mm Dmax Gy 50.5 ± 1.4 51.9 ± 1.7 45.7 ± 7.4
Brainstem Dmax Gy 27.4 ± 7.45 29.07 ± 1.9 25.94 ± 5.9 0.1 0.1 0.037
Larynx Dmean Gy 45.2 ± 6.1 44.7 ± 5.8 43.3 ± 8.7
Plexus brachialis Ipsilateral D2% Gy 58.5 ± 0.4 58.0 ± 0.9 57.6 ± 1.6 0.345 0.345 0.138
COIN 0.306 ± 0.159 0.398 ± 0.433 0.505 ± 0.172 0.116 0.075 0.028
Plexus brachialis contralat-
eral
D2% Gy 58.5 ± 0.3 58.1 ± 0.3 57.9 ± 1.4 0.463 0.046 0.138
COIN 0.279 ± 0.141 0.355 ± 0.155 0.535 ± 0.178 0.028 0.028 0.028
Mandibula Dmean Gy 46.0 ± 7.2 48.7 ± 6.1 44.2 ± 7.7 0.014 0.025 0.1
D2% Gy 70.7 ± 3.3 71.2 ± 2.6 71.9 ± 2.5 0.2 0.6 0.2
Page 6 of 10Pigorsch et al. Radiat Oncol          (2020) 15:253 
SIB70Gy had best coverage with the IMRT plan 
(CVF 0.997 ± 0.002 vs. 0.995 ± 0.002 for VMAT and 
0.995 ± 0.005 for HT). HT achieved a very good 
HTCI (0.827 ± 0.034) vs. 0.759 ± 0.01 for VMAT and 
0.773 ± 0.035 for IMRT. As a consequence of the 
high HTCI, the tomotherapy plan reached the high-
est conformation number (CN) 0.823 ± 0.035 com-
pared to IMRT (CN 0.769 ± 0.035) and VMAT (CN 
0.754 ± 0.024) for SIB70Gy. Homogeneity calcu-
lation favors HT (HI: HT 1.141 ± 0.016 vs. IMRT 
1.142 ± 0.009 vs. VMAT 1.145 ± 0.01).
For SIB56Gy, the coverage parameter CVF was 
comparable in all three RT technique plans between 
0.983 ± 0.006 and 0.986 ± 0.004. In contrast to the 
SIB77Gy and SIB70Gy, the SIB56Gy conformity analysis 
using HTCI and CN favors VMAT (HTCI: 0.747 ± 0.024 
and CN 0.739 ± 0.023). IMRT (HTCI: 0.731 ± 0.029; 
CN: 0.723 ± 0.031) and HT (HTCI: 0.728 ± 0.034; CN: 
0.719 ± 0.033) achieved lower results. Plan examples 
are given in Fig. 1.
The comparison check done by Student’s two-sided 
paired t-test (IMRT vs. HT, IMRT vs. VMAT, and HT 
vs. VMAT) reveals a significant difference concern-
ing  Dmean,  D2% and  D5% for SIB77Gy between all RT 
techniques, favoring HT.  D5% differed significantly for 
SIB70Gy and SIB56Gy with the best results by HT.
Dmean to the ipsilateral parotid gland varied 
between 31.1 ± 4.0  Gy (HT), 33.1 ± 4.4  Gy (IMRT) 
and 32.8 ± 4.8  Gy (VMAT) and contralateral between 
22.6 ± 5.5  Gy (HT), 26.2 ± 3.6  Gy (IMRT) and 
26.3 ± 3.9  Gy (VMAT). HT showed minimally bet-
ter results for ipsilateral parotid glands vs. VMAT and 
IMRT. IMRT and VMAT achieved comparable results. 
For the contralateral parotid gland, there was only an 
advantage of HT compared to VMAT (p = 0.043).
The  Dmax for the spinal cord plus 5 mm was compara-
bly safe for all kinds of radiotherapy. Interestingly, HT 
reached the lowest  Dmax 45.7 ± 8.2 Gy, but the highest 
standard deviation.
For comparison of the plexus brachialis, this OAR 
was also discriminated between ipsilateral and con-
tralateral localization. Concerning  D2% only for the 
contralateral plexus, a small significant difference was 
reached for IMRT vs. VMAT, favoring IMRT.
The  Dmean of the mandible was 44.2 ± 8.5  Gy for 
HT, 46.0 ± 7.9  Gy for VMAT, and 48.7 ± 6.7  Gy for 
IMRT. VMAT and HT were significantly better than 
IMRT (VMAT vs. IMRT p = 0.025).  Dmean of the man-
dible could be lowered by HT compared to VMAT 
(p = 0.014).  D2% for mandible was comparably high 
for all used techniques (VMAT: 70.7 ± 3.6  Gy; IMRT: 
71.2 ± 2.8 Gy and HT: 71.9 ± 2.7 Gy).
Discussion
The aim of this planning study was to investigate the 
planning options for the first six patients enrolled in the 
pre-study of the ESCALOX trial. Thus, IMRT, VMAT, 
and HT planning algorithms and the corresponding RT 
plans were compared and checked for the constraints as 
determined by the trial protocol [12]. Different plan qual-
ity parameters were calculated from DVH for all plan-
ning target volumes (SIB77Gy, SIB70Gy, and SIB56Gy) 
in order to compare all RT techniques. Dose coverage, 
dose conformity, and homogeneity were analyzed. For 
SIB77Gy, SIB70Gy, and SIB56Gy, the coverage of all 
RT modalities was comparable. HT gained best results 
for SIB77Gy concerning conformity (HTCI and CN) 
and homogeneity defined by the HI. Concerning cov-
erage (CVF) of HT for SIB77Gy, there was a small gap 
between HT and VMAT and IMRT, which seems clini-
cally irrelevant.
The SIB70Gy volume encompassed the shell between 
the margin of SIB77Gy and SIB70Gy. Best coverage 
for SIB70Gy was achieved by IMRT. Conformity and 
homogeneity favored HT. The analysis of SIB56Gy—the 
volume for elective nodal irradiation—revealed a com-
parable coverage for all RT modalities. Best conformity 
was reached by VMAT, superior homogeneity by HT. 
Thus, HT is favored for conformity defined by HTCI and 
CN for the SIB77Gy and SIB70Gy. Best performance for 
homogeneity (HI) in all SIBs was achieved only by HT, 
followed by IMRT. Important DVH parameters describ-
ing the steepness of the dose gradient as  D2 or  D5 as well 
as  Dmean showed better results for HT, but no differences 
between IMRT and VMAT. Despite the shown advantage 
of HT, all RT modalities fulfilled the dose specification of 
the trial protocol: 50% of the PTV volumes (SIB77, SIB70, 
SIB56) should receive no more than 79.3 Gy, 72.1 Gy, and 
57.7 Gy, respectively.
Differding et  al. compared in a RT planning study 
the potential of VMAT and HT in part 1 for best tar-
get coverage and in part 2 for maximal OAR sparing [5, 
21]. This was an FDG-PET based delineation for dose 
painting planning study on datasets of five patients with 
oropharyngeal cancer. HT and VMAT achieved com-
parable results for target coverage (PTV 70  Gy (SIB) 
and PTV 56 Gy applied in 35 fractions) and OAR spar-
ing. Slight differences were seen for conformity of PTV 
56 Gy favoring HT. The authors concluded that HT and 
VMAT were able to deliver similar dose distributions for 
FDG-PET-based dose escalation for the concept of dose 
painting by numbers. The good results for VMAT were 
at the cost of four arcs. The planning physicists extended 
the limits of the TPS by re-optimization of the RT plans 
after comparing their results to the other TPS results. 
For our planning scenario, both physicists did the same. 
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Fig. 1 Examples of isodose distribution and DVH of VMAT, IMRT and HT for patient 2. SIB colours: SIB 77 Gy—yellow, SIB 70 Gy—orange, SIB 56 Gy—
red. OAR colours: brainstem—magenta, left parotid gland—green, right parotid gland—blue, spinal cord—brown, left plexus brachialis—light 
green, right plexus brachialis—light blue
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In order to yield comparable results for target coverage 
and to minimize the OAR dose, VMAT applies the dose 
by using three arcs. Despite one additional arc compared 
to a routine head and neck RT plan, the beam on time is 
lower than the amount of time of application of an HT 
plan. This indicates that the probability of intra-fraction 
motion is smaller by VMAT than with HT.
Thorwarth et  al. compared 9-field step and shoot 
IMRT with HT for inhomogeneous dose distribution by 
dose painting by numbers for dose escalation to hypoxic 
subvolumes. HT achieved a higher degree of conform-
ity. Therefore, in this planning competition, the authors 
summarized both implemented techniques (IMRT and 
HT) as suitable for dose escalation [6]. Only small differ-
ences for target coverage were seen by Stromberger et al. 
for planning comparison of a SIB concept in bilateral and 
unilateral neck irradiation for intensity modulated proton 
therapy (IMPT), HT, and VMAT [3].
Concerning OARs, the comparison of DVH param-
eters for parotid gland, brainstem, and mandible saw HT 
ahead in our investigation. Despite the favored position 
of HT in many parameters, IMRT and VMAT ensured 
safe coverage of target volumes and adherence to the 
OAR constraints per trial protocol. The small differences 
seen in the head-to-head comparison will probably have 
no impact on clinical outcome. Other groups investigat-
ing different RT techniques and fractionation concepts 
for head and neck cancer hypothesized no clinical impact 
of small dosimetric differences [5, 7] as well. Comparing 
 Dmean to the ipsilateral parotid gland, we achieved the 
lowest dose by HT (31.1  Gy). There was a difference of 
2 Gy compared to IMRT (33.1 Gy). HT reached also best 
contralateral  Dmean (22.6 Gy) to the parotid gland (VMAT 
and IMRT > 26  Gy). Jacob et  al. investigated the influ-
ence of leaf and jaw parameter on plan quality for head 
and neck RT in nine patients by IMRT, VMAT, and HT. 
They concluded that all plans fulfilled OAR constraints, 
but HT lowered the dose to the parotid glands by best 
dose homogeneity. Changes of leaf thickness and jaw 
width had no additional benefit for OAR sparing [22]. 
Inconsistent results favoring one technique over another 
for dose reduction to salivary glands are reported [9, 
23–27]. The groups of Wiezorek [27] and Holt [28] exam-
ined head and neck RT plans created by diverse IMRT 
techniques and various machine parameters between 
different institutions, the conclusion was the same as in 
many single center experiences: good target coverage 
and acceptable OAR sparing for all techniques with slight 
preference. At one point, HT was superior, on occasion 
VMAT or IMRT. Both multicenter planning comparison 
trials delineated the PTV (respective SIB volumes) and 
OARs in the core unit. Thus, the uncertainty in target 
volume delineation was excluded and the results clearly 
concentrate on the physical aspect of RT planning and 
treatment delivery. The aim of this study consisted in 
proof of principle for using different TPS for planning 
of real patients in preparation of a multicenter study. 
For the purpose of initiating a multicenter IMRT-trial, 
a dummy run for all participating centers with a central 
QA core unit would be necessary. Early on, this was rec-
ommended by Wallner et al. in 1989 [29] and renewed by 
McDowell in 2019 [10]. In order to reduce unnecessary 
dose deposition to OARs and surrounding healthy tissue, 
the trial protocol recommended triple re-planning [12] 
based on results of the work of Duma et al. [30] and oth-
ers e.g. [31]. The onboard imaging units of linear accel-
erators increase the accuracy of patient positioning (daily 
CB-CT, MV-CT) and allow for adaptive planning. Con-
sequently, the target volumes and OARs can be observed 
and adapted if necessary.
This analysis was done with the primary image set for 
initial RT planning. The re-planning scenarios as per-
formed for each patient during the pre-study are not 
shown.
MRI for GTV definition is important for safety of tar-
get and OAR delineation due to better spatial resolu-
tion. Over the last years, many results were confirmed 
for implementation of molecular imaging and widened 
sequences of MRI, e.g. diffusion-weighted MRI for GTV 
definition [32] and also better definition of OAR, for 
instance, swallowing structures [33]. In a dummy run, 
Felice et al. demonstrated the smaller GTV definition and 
lower inter-observer variability for MRI-based contour-
ing compared to CT-based target volume definition [34]. 
Implementation of molecular imaging is a widely inves-
tigated field, not only in RT planning of head and neck 
cancer [35]. Some trials investigating dose escalation 
integrate the PET signal by employing different tracers 
and voxel-based RT-planning [5, 6, 36–39]. Hence, the 
dose escalation strategy based on PET data to overcome 
troubleshooters like hypoxia or proliferation is not clear 
[40]. Until now, no large randomized trial on this topic 
has been published. Despite the advent of implementa-
tion of biological imaging into target volume delineation 
for head and neck cancer treatment aimed at attacking, 
for instance, hypoxic subvolumes by dose escalation, we 
resigned at the level of the pre-study of the performance 
of 18-F-FMISO-PET.
We generated in one center the presented results 
by calculating 18 different RT plans for a dose escala-
tion study by using the two TPS on datasets of six real 
patients. The planning group consisted of two radiation 
oncologists (SP and MD) and two physicists (SK and 
MO) experienced in the TPS for head and neck cancer 
planning. Our results are comparable to those of other 
investigators of single or multicenter planning studies 
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despite our homogeneous in-house team. The statisti-
cal results of small sample sizes always require careful 
interpretation. A significant difference detection calls 
for a defined number of dose values or a large difference 
between the values of the comparators. Possible sources 
for bias are discussed by van Gestel et  al. contributing 
to different interpretations of planning comparisons by 
various investigators. One of the drawbacks of our study 
is the use of only those TPS which were available at our 
department and the limited number of patients. How-
ever, in light of these limitations, it was possible to reach 
the planning objectives defined by the ESCALOX trial 
protocol [12].
Conclusion
The analysis of the quality parameters for RT planning 
revealed that the tested TPS can produce comparable 
plan quality for this dose escalation trial. Despite the very 
good results of HT planning for coverage, conformity, 
and homogeneity of these plans, also the TPS for calcula-
tion of VMAT and IMRT achieved acceptable results for 
a double simultaneous integrated boost concept for dose 
escalation in head and neck cancer delivered by IMRT 
or VMAT. The tested TPS and IMRT-techniques are 
allowed for the ESCALOX trial.
Supplementary information
Supplementary information accompanies this paper at https ://doi.
org/10.1186/s1301 4-020-01693 -2.
Additional file 1. Raw data from DVH for analysis of plan comparison 
parameter.
Abbreviations
AAA : Anisotropic Analytical Algorithm; ALARA : As Low as Reasonable Achiev-
able; CB-CT: Cone beam CT; CN: Conformation number; COIN: Conformity 
index; CT: Computed tomography; CVF: Coverage factor; D: Dose; DVH: 
Dose Volume Histogram; FDG-PET: Fluorodesoxyglucose positron emission 
tomography; 18-F-FMISO-PET: 18-Fluoro-Fluoromisonidazol positron emission 
tomography; GTV: Gross tumor volume; HI: Homogeneity index; HT: Helical 
tomotherapy; HTCI: Healthy tissue conformity index; IMRT: Intensity Modu-
lated RadioTherapy; MRI: Magnetic Resonance Imaging; MV-CT: Megavoltage 
CT; OAR: Organ at risk; PTV: Planning target volume; QA: Quality assurance; RT: 
Radiotherapy; SIB: Simultaneous integrated boost; TPS: Treatment planning 
system; TV: Target volume; TVRI: Irradiated target volume encompassed by 
reference dose 95%-isodose; VMAT: Columetric Modulated Arc Therapy; VRI: 
Irradiated volume encompassed by reference 95%-isodose.
Acknowledgements
We would like to thank all the participating patients of this trial. The authors 
gratefully acknowledge the native speaking support of Dr Sabrina Renfro-Kohl.
Authors’ contributions
PTV-definition by SP and MD. RT plans were evaluated quantitatively and 
qualitatively (isodose curves and color wash) by two physicians (SP and MD). 
Treatment plan optimization: SK, MO. Statistical analysis: MM, KK. Manuscript 
writing: SP. JW and SC discussed the data and manuscript writing. All authors 
read and approved the final manuscript.
Funding
Open Access funding enabled and organized by Projekt DEAL. The ESCALOX 
trial was supported by the Deutsche Forschungsgemeinschaft (DFG); Grant 
No.: MO-363/4-1.
Availability of supporting data
The dataset supporting the conclusions of this article is included within the 
article and its Additional file 1.
Ethical approval and consent to participate
The final protocol was approved by the ethics committee of the Medical 
Faculty of the Technical University of Munich (2847/10 Af ) and the German 
Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimit-
tel und Medizinprodukte—BfArM; BfArM-registration number 4036421) and 
the German Federal Office of Radiation Protection (Bundesamt für Strahlens-
chutz—BfS) (BfS-registration number Z5-22463/2–2011-011).Written informed 
consent was obtained from each patient in oral and written form before 
inclusion in the trial. Nature, scope and possible consequences of which has 
been explained by the responsible physician.
Consent for publication
All authors agreed to publish the presented results und read the final version 
of the submitted paper.
Competing interests
No one of the authors declare conflict of interest for this work.
Author details
1 Department of Radiation Oncology, Technical University of Munich 
(TUM), School of Medicine, Klinikum Rechts Der Isar, Ismaninger Straße 22, 
81675 Munich, Germany. 2 Institute of Radiation Medicine (IRM), Helmholtz 
Zentrum München, Ingolstädter Landstraße 1, Neuherberg, Germany. 
3 Department of Radiation Oncology, University Hospital Zurich, Rämistrasse 
100, Zurich, Switzerland. 
Received: 28 July 2020   Accepted: 21 October 2020
References
 1. Lauve A, Morris M, Schmidt-Ullrich R, Wu Q, Mohan R, Abayomi O, et al. 
Simultaneous integrated boost intensity-modulated radiotherapy for 
locally advanced head-and-neck squamous cell carcinomas: II—clinical 
results. Int J Radiat Oncol Biol Phys. 2004;60(2):374–87. 
 2. Mohan R, Wu Q, Manning M, Schmidt-Ullrich R. Radiobiological consid-
erations in the design of fractionation strategies for intensity-modulated 
radiation therapy of head and neck cancers. Int J Radiat Oncol Biol Phys. 
2000;46(3):619–30. 
 3. Stromberger C, Wlodarczyk W, Marnitz S, Jamil B, Budach V, Raguse JD, 
et al. Simultaneous integrated boost (SIB): RapidArc and tomotherapy 
plan comparison for unilateral and bilateral neck irradiation. Anticancer 
Res. 2015;35(5):2991–7. 
 4. Fakhrian K, Oechsner M, Kampfer S, Schuster T, Molls M, Geinitz H. 
Advanced techniques in neoadjuvant radiotherapy allow dose escalation 
without increased dose to the organs at risk : planning study in esopha-
geal carcinoma. Strahlenther Onkol. 2013;189(4):293–300. 
 5. Differding S, Sterpin E, Hermand N, Vanstraelen B, Nuyts S, de Patoul N, 
et al. Radiation dose escalation based on FDG-PET driven dose painting 
by numbers in oropharyngeal squamous cell carcinoma: a dosimetric 
comparison between TomoTherapy-HA and RapidArc. Radiat Oncol. 
2017;12(1):59. 
 6. Thorwarth D, Eschmann SM, Paulsen F, Alber M. Hypoxia dose 
painting by numbers: a planning study. Int J Radiat Oncol Biol Phys. 
2007;68(1):291–300. 
 7. Clemente S, Wu B, Sanguineti G, Fusco V, Ricchetti F, Wong J, et al. Smart-
Arc-based volumetric modulated arc therapy for oropharyngeal cancer: a 
dosimetric comparison with both intensity-modulated radiation therapy 
and helical tomotherapy. Int J Radiat Oncol Biol Phys. 2011;80(4):1248–55. 
Page 10 of 10Pigorsch et al. Radiat Oncol          (2020) 15:253 
 8. Ekici K, Pepele EK, Yaprak B, Temelli O, Eraslan AF, Kucuk N, et al. 
Dosimetric comparison of helical tomotherapy, intensity-modulated 
radiation therapy, volumetric-modulated arc therapy, and 3-dimensional 
conformal therapy for the treatment of T1N0 glottic cancer. Med Dosim. 
2016;41(4):329–33. 
 9. Servagi Vernat S, Ali D, Puyraveau M, Viard R, Lisbona A, Fenoglietto P, 
et al. Is IMAT the ultimate evolution of conformal radiotherapy? Dosi-
metric comparison of helical tomotherapy and volumetric modulated 
arc therapy for oropharyngeal cancer in a planning study. Physica Med. 
2014;30(3):280–5. 
 10. McDowell L, Corry J. Radiation therapy quality assurance in head and 
neck radiotherapy—moving forward. Oral Oncol. 2019;88:180–5. 
 11. Peters LJ, O’Sullivan B, Giralt J, Fitzgerald TJ, Trotti A, Bernier J, et al. Critical 
impact of radiotherapy protocol compliance and quality in the treatment 
of advanced head and neck cancer: results from TROG 02.02. J Clin Oncol. 
2010;28(18):2996–3001. 
 12. Pigorsch SU, Wilkens JJ, Kampfer S, Kehl V, Hapfelmeier A, Schlager C, et al. 
Do selective radiation dose escalation and tumour hypoxia status impact 
the loco-regional tumour control after radio-chemotherapy of head & 
neck tumours? The ESCALOX protocol. Radiat Oncol. 2017;12(1):45. 
 13. Feuvret L, Noel G, Mazeron JJ, Bey P. Conformity index: a review. Int J 
Radiat Oncol Biol Phys. 2006;64(2):333–42. 
 14. Armstrong J, Raben A, Zelefsky M, Burt M, Leibel S, Burman C, et al. 
Promising survival with three-dimensional conformal radiation therapy 
for non-small cell lung cancer. Radiother Oncol. 1997;44(1):17–22. 
 15. van’t Riet A, Mak AC, Moerland MA, Elders LH, van der Zee W. A conforma-
tion number to quantify the degree of conformality in brachytherapy and 
external beam irradiation: application to the prostate. Int J Radiat Oncol 
Biol Phys. 1997;37(3):731–6. 
 16. Eisbruch A, Kim HM, Terrell JE, Marsh LH, Dawson LA, Ship JA. Xerostomia 
and its predictors following parotid-sparing irradiation of head-and-neck 
cancer. Int J Radiat Oncol Biol Phys. 2001;50(3):695–704. 
 17. Eisbruch A, Rhodus N, Rosenthal D, Murphy B, Rasch C, Sonis S, et al. The 
prevention and treatment of radiotherapy—induced xerostomia. Semin 
Radiat Oncol. 2003;13(3):302–8. 
 18. Eisbruch A, Ship JA, Dawson LA, Kim HM, Bradford CR, Terrell JE, et al. 
Salivary gland sparing and improved target irradiation by conformal and 
intensity modulated irradiation of head and neck cancer. World J Surg. 
2003;27(7):832–7. 
 19. Rancati T, Schwarz M, Allen AM, Feng F, Popovtzer A, Mittal B, et al. Radia-
tion dose-volume effects in the larynx and pharynx. Int J Radiat Oncol 
Biol Phys. 2010;76(3 Suppl):S64–9. 
 20. Baltas D, Kolotas C, Geramani K, Mould RF, Ioannidis G, Kekchidi M, et al. A 
conformal index (COIN) to evaluate implant quality and dose specifica-
tion in brachytherapy. Int J Radiat Oncol Biol Phys. 1998;40(2):515–24. 
 21. Differding S, Sterpin E, Janssens G, Hanin FX, Lee JA, Gregoire V. Meth-
odology for adaptive and robust FDG-PET escalated dose painting by 
numbers in head and neck tumors. Acta Oncol. 2016;55(2):217–25. 
 22. Jacob V, Bayer W, Astner ST, Busch R, Kneschaurek P. A planning compari-
son of dynamic IMRT for different collimator leaf thicknesses with helical 
tomotherapy and RapidArc for prostate and head and neck tumors. 
Strahlenther Onkol. 2010;186(9):502–10. 
 23. Stromberger C, Ghadjar P, Marnitz S, Thieme AH, Jahn U, Raguse JD, et al. 
Comparative treatment planning study on sequential vs simultaneous 
integrated boost in head and neck cancer patients: differences in dose 
distributions and potential implications for clinical practice. Strahlenther 
Onkol. 2016;192(1):17–24. 
 24. Stromberger C, Cozzi L, Budach V, Fogliata A, Ghadjar P, Wlodarczyk W, 
et al. Unilateral and bilateral neck SIB for head and neck cancer patients : 
Intensity-modulated proton therapy, tomotherapy, and RapidArc. Strahl-
enther Onkol. 2016;192(4):232–9. 
 25. Van Gestel D, van Vliet-Vroegindeweij C, Van den Heuvel F, Crijns W, 
Coelmont A, De Ost B, et al. RapidArc, SmartArc and TomoHD compared 
with classical step and shoot and sliding window intensity modulated 
radiotherapy in an oropharyngeal cancer treatment plan comparison. 
Radiat Oncol. 2013;8:37. 
 26. Van Gestel D, De Kerf G, Wouters K, Crijns W, Vermorken JB, Gregoire V, 
et al. Fast Helical Tomotherapy in a head and neck cancer planning study: 
is time priceless? Radiat Oncol. 2015;10:261. 
 27. Wiezorek T, Brachwitz T, Georg D, Blank E, Fotina I, Habl G, et al. Rotational 
IMRT techniques compared to fixed gantry IMRT and tomotherapy: 
multi-institutional planning study for head-and-neck cases. Radiat Oncol. 
2011;6:20. 
 28. Holt A, Van Gestel D, Arends MP, Korevaar EW, Schuring D, Kunze-Busch 
MC, et al. Multi-institutional comparison of volumetric modulated arc 
therapy vs intensity-modulated radiation therapy for head-and-neck 
cancer: a planning study. Radiat Oncol. 2013;8:26. 
 29. Wallner PE, Lustig RA, Pajak TF, Robinson G, Davis LW, Perez CA, et al. 
Impact of initial quality control review on study outcome in lung and 
head/neck cancer studies—review of the Radiation Therapy Oncology 
Group experience. Int J Radiat Oncol Biol Phys. 1989;17(4):893–900. 
 30. Duma MN, Kampfer S, Schuster T, Winkler C, Geinitz H. Adaptive radio-
therapy for soft tissue changes during helical tomotherapy for head and 
neck cancer. Strahlenther Onkol. 2012;188(3):243–7. 
 31. Castadot P, Geets X, Lee JA, Gregoire V. Adaptive functional image-guided 
IMRT in pharyngo-laryngeal squamous cell carcinoma: is the gain in dose 
distribution worth the effort? Radiother Oncol. 2011;101(3):343–50. 
 32. Gregoire V, Thorwarth D, Lee JA. Molecular imaging-guided radiotherapy 
for the treatment of head-and-neck squamous cell carcinoma: does it 
fulfill the promises? Semin Radiat Oncol. 2018;28(1):35–45. 
 33. Alterio D, Ciardo D, Preda L, Argenone A, Caspiani O, Micera R, et al. 
Contouring of the pharyngeal superior constrictor muscle (PSCM). A 
cooperative study of the Italian Association of Radiation Oncology (AIRO) 
Head and Neck Group. Radiother Oncol. 2014;112(3):337–42. 
 34. de Felice F, Musio D, Bulzonetti N, Maghella F, Tombolini V. Target 
volume delineation based on diffusion-weighted magnetic resonance 
imaging for locally advanced head and neck cancer. Anticancer Res. 
2016;36(8):4181–5. 
 35. Chauhan D, Rawat S, Sharma MK, Ahlawat P, Pal M, Gupta G, et al. 
Improving the accuracy of target volume delineation by combined use 
of computed tomography, magnetic resonance imaging and positron 
emission tomography in head and neck carcinomas. J Cancer Res Therap. 
2015;11(4):746–51. 
 36. Welz S, Monnich D, Pfannenberg C, Nikolaou K, Reimold M, La Fougere C, 
et al. Prognostic value of dynamic hypoxia PET in head and neck cancer: 
Results from a planned interim analysis of a randomized phase II hypoxia-
image guided dose escalation trial. Radiother Oncol. 2017;124(3):526–32. 
 37. Berwouts D, Olteanu LA, Duprez F, Vercauteren T, De Gersem W, De Neve 
W, et al. Three-phase adaptive dose-painting-by-numbers for head-and-
neck cancer: initial results of the phase I clinical trial. Radiother Oncol. 
2013;107(3):310–6. 
 38. Madani I, Duprez F, Boterberg T, Van de Wiele C, Bonte K, Deron P, et al. 
Maximum tolerated dose in a phase I trial on adaptive dose painting by 
numbers for head and neck cancer. Radiother Oncol. 2011;101(3):351–5. 
 39. Duprez F, De Neve W, De Gersem W, Coghe M, Madani I. Adaptive dose 
painting by numbers for head-and-neck cancer. Int J Radiat Oncol Biol 
Phys. 2011;80(4):1045–55. 
 40. Hamming-Vrieze O, Navran A, Al-Mamgani A, Vogel WV. Biological PET-
guided adaptive radiotherapy for dose escalation in head and neck can-
cer: a systematic review. Q J Nucl Med Mol Imaging. 2018;62(4):349–68. 
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
